Literature DB >> 8110730

Human immune response to monoclonal antibodies.

M B Khazaeli1, R M Conry, A F LoBuglio.   

Abstract

Monoclonal antibodies either of mouse, mouse/human chimeric, or human origin have been used safely in human trials for a decade. Considerable effort has been committed in investigations of manipulating endogenous immunological activity against tumors and targeting various cytotoxic agents to cancers. These studies have identified several problems that need to be resolved before any such reagents can be used routinely in patients. One of these problems has been the immunogenicity of these monoclonal antibodies. This review article discusses what is known regarding human immune response to monoclonal antibodies and their clinical consequences.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8110730     DOI： 10.1097/00002371-199401000-00006

Source DB:  PubMed          Journal:  J Immunother Emphasis Tumor Immunol        ISSN： 1067-5582


  40 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

Review 2.  Generation and production of engineered antibodies.

Authors:  Sergey M Kipriyanov; Fabrice Le Gall
Journal:  Mol Biotechnol       Date:  2004-01       Impact factor: 2.695

3.  Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library.

Authors:  Peter Ellmark; Camilla Ottosson; Carl A K Borrebaeck; Ann-Christin Malmborg Hager; Christina Furebring
Journal:  Immunology       Date:  2002-08       Impact factor: 7.397

Review 4.  Demystified...recombinant antibodies.

Authors:  K A Smith; P N Nelson; P Warren; S J Astley; P G Murray; J Greenman
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

Review 5.  Oligoclonal antibodies to target the ErbB family.

Authors:  Jimson W D'Souza; Matthew K Robinson
Journal:  Expert Opin Biol Ther       Date:  2015-05-02       Impact factor: 4.388

Review 6.  Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.

Authors:  Michael Campoli; Robert Ferris; Soldano Ferrone; Xinhui Wang
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

7.  Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.

Authors:  Robert A Larsen; Peter G Pappas; John Perfect; Judith A Aberg; Arturo Casadevall; Gretchen A Cloud; Robert James; Scott Filler; William E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

8.  High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells.

Authors:  Bin Lou; Xue-Ling Liao; Man-Ping Wu; Pei-Fang Cheng; Chun-Yan Yin; Zheng Fei
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

9.  OKT3 monitoring in the treatment of steroid-resistant acute rejection of hepatotransplant recipients.

Authors:  P Brusa; R Casullo; F Dosio; L Cattel; S Beltramini; R Chiappetta; L Tosetti; E Andorno; M Salizzoni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

Review 10.  Immunotherapy of cancer.

Authors:  Hossein Borghaei; Mitchell R Smith; Kerry S Campbell
Journal:  Eur J Pharmacol       Date:  2009-10-20       Impact factor: 4.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.